Literature DB >> 3112172

T-cell surface molecules involved in the induction and expression of lymphokine-activated killing of autologous and allogeneic tumor targets.

A L Nashed, B Mukherji.   

Abstract

The cellular interactions and the surface molecules involved in the generation and the expression of lymphokine-activated killer-cell (LAK) activities in vitro in blood mononuclear cells (BMN) from cancer patients and healthy individuals against autologous and allogeneic tumors were studied. The depletion of a plastic-adherent population(s) from BMN at the initiation of in vitro cultures in recombinant interleukin-2 (rIL-2) markedly interfered with the generation of LAK activities. Readdition of the same number of irradiated autologous plastic-adherent cells to the nonadherent population restored the generation of LAK. The requirement of the plastic-adherent population(s) in in vitro induction of LAK activities was observed only in autologous situations. Furthermore, selective modulations of CD3 and CD2 receptors on BMN with the appropriate monoclonal antibodies (MAb) during the induction phases of LAK responses profoundly inhibited the generation of LAK. Thus, unhindered expression of CD2 molecules and CD3 molecules were necessary for the maximum cytotoxic activation of non-antigen-driven effector cells in short-term cultures in rIL-2.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112172     DOI: 10.1007/bf00915549

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  11 in total

1.  Modulation of surface T11 molecules induced by monoclonal antibodies: analysis of the functional relationship between antigen-dependent and antigen-independent pathways of human T cell activation.

Authors:  A Moretta; D Olive; A Poggi; G Pantaleo; C Mawas; L Moretta
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

2.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

3.  Suppression of human T-cell mitogenesis and E-rosette formation by the monoclonal antibody OKT11A.

Authors:  J Van Wauwe; J Goossens; W Decock; P Kung; G Goldstein
Journal:  Immunology       Date:  1981-12       Impact factor: 7.397

4.  Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein.

Authors:  R F Siliciano; J C Pratt; R E Schmidt; J Ritz; E L Reinherz
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

Review 5.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

7.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

8.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  Clonal analysis of cytotoxic T cell response against human melanoma.

Authors:  B Mukherji; T J MacAlister
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.